Design and Rationale of the CLASP II TR Randomized Trial for Severe Tricuspid Regurgitation.
Gorav Ailawadi, Charles J Davidson, Allen S Anderson...
https://pubmed.ncbi.nlm.nih.gov/42855029/Actively Recruiting
Led by Edwards Lifesciences · Updated on 2026-09-14
1270
Participants Needed
79
Research Sites
208 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System for patients with severe tricuspid regurgitation who have symptoms and are at an intermediate or higher risk of mortality from tricuspid valve surgery. This randomized, controlled trial compares the device combined with optimal medical therapy OMT to OMT alone. The study is conducted at multiple centers and sponsored by Edwards Lifesciences. Participants are assigned to one of several groups receiving the Edwards PASCAL system plus OMT, OMT alone, or the device with OMT if not eligible for randomization. The transcatheter procedure repairs the tricuspid valve without open surgery. Follow-up visits occur at hospital discharge, 30 days, 3 months, 6 months, and then annually for up to 5 years, allowing long-term monitoring of outcomes. During the study, participants will undergo assessments including quality of life questionnaires, heart imaging, and monitoring for heart failure hospitalizations, mortality, and valve-related events. The main outcome measured at 6 months includes a combination of death, heart device implantation or transplant, valve interventions, hospital admissions for heart failure, and improvement in quality of life. Safety and effectiveness data will be collected throughout the follow-up period of up to 5 years.
CONDITIONS
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
E
Edwards TMTT Clinical Affairs
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Edwards Lifesciences
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | PASCAL System + OMT | OMT alone | Current TEER practice |
|---|---|---|---|
| What it is | PASCAL edge‑to‑edge transcatheter tricuspid valve repair system used in combination with optimal medical therapy | Standard optimal medical therapy for severe tricuspid regurgitation without device intervention | Transcatheter edge‑to‑edge repair (TEER) using devices like MitraClip for tricuspid regurgitation is emerging in clinical practice |
| Role in trial | Investigational device arm combining PASCAL with OMT | Control arm receiving optimal medical therapy only | Contextual comparator representing current device‑based TR repair in practice |
| Primary use | Interventional device to reduce tricuspid regurgitation in addition to medical therapy | Medical management of severe tricuspid regurgitation without device intervention | Device‑based tricuspid repair performed in current practice for symptomatic TR |
| How it is performed | Percutaneous catheter‑based edge‑to‑edge repair using the PASCAL device plus ongoing medical therapy | Patients continue guideline‑based medical treatments without device procedure | Percutaneous edge‑to‑edge repair with TEER devices such as MitraClip adapted for tricuspid valve |
| Evidence status | Efficacy and safety are being evaluated in this randomized pivotal trial | Efficacy as comparator control; outcomes established through existing clinical practice | Effectiveness supported by real‑world registry and observational data showing improvements in TR severity, functional status, and QoL at one year |
| Important risks | Not yet established outside trial; procedural risks under evaluation | Risks related to underlying disease and medical management rather than procedural device exposure | Real‑world data report safety in practice settings, though procedural complications can occur |
| Important limitations | Trial results not yet available; findings pending completion of pivotal randomized study | Medical therapy alone may not sufficiently address regurgitation in many patients | Evidence comes from observational and registry data without randomized comparison to OMT or each other |
| Patient‑relevant outcomes | Pending; trial includes endpoints like survival, hospitalization, and quality of life but results not yet available | Outcomes reflect standard care trajectory but may include persistent symptoms, hospitalizations, and mortality | Real‑world data show improvements in functional status (NYHA class), quality of life, and reduction in hospitalizations at one year |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 5 years
Participants receive either the Edwards PASCAL device plus optimal medical therapy or optimal medical therapy alone to treat tricuspid regurgitation.
Visits at discharge, 30 days, 3 months, 6 months, and annually up to 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Gorav Ailawadi, Charles J Davidson, Allen S Anderson...
https://pubmed.ncbi.nlm.nih.gov/42855029/Edwards Lifesciences
Lead Sponsor